In cells that had been treated with BEZ235, phosphorylation of AKT at both residues Thr308 and Ser473 was decreased (p-AKT/Thr308 and p-AKT/Ser473, respectively), resulting in a reduction of phosphorylated S6 (p-S6), as previously described for human glioma and lung cancer cells (Herrera et al., 2011; Liu et al., 2009). This evidence concerns the gene AKT1 and central nervous system cancer.